Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria.[L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance.[L11830] In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.
Sulfamethoxazole and Trimethoprim (Double Strength)
Septra DS Tablets
sulfamethoxazole-trimethoprim (SMZ)
Bactrim Roche Inj
Sulfamethoxazole and Trimethoprim
SULFAMETHOXAZOLE AND TRIMETHOPRIM double strength
Sulfatrim DS
Sulfamethoxazole and Trimethoprim Injection, BP
Apo Sulfamethoxazole Tab 500mg
Bactrim DS
Roubac Tab 160/800
Septra
Septra Injection
Sulfamethoxazole and Trimethoprim for Injection, USP
Sulfatrim Pediatric
Riva-sep DS
Trisulfa Tab
Sulfamethoxazole and Trimethoprim Double Strength
Teva-trimel DS
Septra Pediatric Suspension
Bactrim Roche Tab
Trisulfa DS Tab
Septra DS
Nu-cotrimox Sus 40/8mg/ml
SULFAMETHOXAZOLE and TRIMETHOPRIM
Sulfamethoxazole and Trimethoprim Tablets
Nu-cotrimox Tab 400/80mg
Apo-sulfatrim Oral Suspension
Indication
Sulfamethoxazole is indicated in combination with trimethoprim, in various formulations, for the following infections caused by bacteria with documented susceptibility: urinary tract infections, acute otitis media in pediatric patients (when clinically indicated), acute exacerbations of chronic bronchitis in adults, enteritis caused by susceptible _Shigella_, prophylaxis and treatment of _Pneumocystis jiroveci_ pneumonia, and travelers' diarrhea caused by enterotoxigenic _E. coli_.[L11830,L11863] In Canada, additional indications include the adjunctive treatment of cholera, treatment of bacillary dysentery, nocardiosis, and second-line treatment of brucellosis in combination with [gentamicin] or [rifampicin].[L11851]
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
